DEEP RESEARCH · HANMI/LIGACHEM BIO

Hanmi Pharmaceutical and LigaChem Bio Collaboration JPM 2026 Milestone Report

Connecting bispecific ADCs, ADC intermediate CDMO work, and obesity/metabolic pipeline momentum

Written: 2026-01-12 · K-biotech partnering/licensing view · Naver Blog original

0. Bottom line first

Official fact: The source covers the 2021 Hanmi-LegoChem bispecific ADC collaboration, the Hanmi Fine Chemical-LigaChem CDMO contract for ADC linker/payload intermediates, Hanmi's HM15275, HM17321, and HM16390, and LigaChem's LCB84, LCB14, and LCB97.

Interpretation: JPMHC 2026 should be treated not as a single news event but as a checkpoint for data, option exercise, overhang resolution, and CDMO orders.

1. A structural step-up for Korean biotech

The post frames 2026 as a structural leap year for Korean pharma and biotech. Easier rate conditions and big pharma's patent cliff raise demand for external innovation, with ADCs and obesity/metabolic therapies presented as the hottest categories.

Within that setup, Hanmi brings obesity and metabolic pipelines, while LigaChem brings ADC platform capability.

2. Bispecific ADC: Pentambody meets ConjuAll

The most important R&D collaboration is the bispecific ADC joint research between Beijing Hanmi and LigaChem. The approach is meant to address single-antigen ADC limitations, tumor heterogeneity, and off-target toxicity by binding two targets at once.

Interpretation: If JPMHC 2026 or AACR 2026 shows joint abstracts or in-vivo efficacy and toxicity data under both names, the collaboration can move from research agreement to pipeline value.

3. Hanmi Fine Chemical CDMO collaboration

Beyond research, Hanmi Fine Chemical's contract manufacturing of ADC linker and payload intermediates for LigaChem is the manufacturing core. The source treats this as Hanmi Fine Chemical's first major extension of cGMP capability into ADC materials.

• LigaChem: secures a domestic high-quality linker/payload supply chain as global licensing expands
• Hanmi group: extends from conventional APIs into high-value ADC intermediate CDMO
• 2026 variable: rising clinical stages and commercialization preparation for assets such as LCB84 and LCB14 could increase material demand

4. Hanmi JPM 2026 checklist

5. LigaChem JPM 2026 checklist

For LigaChem, 2026 is presented as a possible shift from platform validation to cash-flow creation.

Official fact: LCB84 is the key asset in the December 2023 Janssen deal worth USD 1.7 billion, about KRW 2.2 trillion. The source mentions a possible option exercise payment of about USD 200 million, roughly KRW 260 billion.

• LCB84: whether Janssen labels it Core Pipeline or Key Asset
• LCB14: Fosun's China phase 3, possible 2026 China BLA, and Iksuda's US phase 2 entry
• LCB97: Ono's L1CAM ADC IND and clinical entry in the first half of 2026
• Platform expansion: PBD prodrug, immune-modulating payloads, and non-oncology ADC expansion

6. Risks and investment strategy

The source is clear about risks. Hanmi faces overhang and governance aftershocks, clinical delays, and late-mover discount in obesity therapies. LigaChem faces intense ADC competition and dependence on partners such as Janssen, Fosun, and Iksuda.

Interpretation: For Hanmi, obesity momentum should be analyzed together with overhang resolution. For LigaChem, volatility around the LCB84 option-exercise event matters, but CDMO collaboration and platform breadth can strengthen long-term fundamentals.

7. Conclusion

Hanmi is trying to redefine itself as a global obesity/metabolic-disease player through HM15275 and HM17321, while LigaChem is moving toward a cash-generating global ADC platform through Janssen's option and Ono milestones. Their joint research and CDMO links are concrete examples of how Korean pharma and biotech can approach global markets together.